Clinical Trial Details

< Previous Trial     Next Trial >
Study ID VCL-1005-207
Investigator
Title Phase II Trial of Allovectin-7® for Head and Neck Cancer
Conditions Head and Neck Cancer
Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Head and Neck Neoplasms
Carcinoma of the Head and Neck
Interventions Genetic: Allovectin-7®
Phase Phase 3
Purpose The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors. The trial will also examine if treatment can boost the immune system and if this treatment can improve the time to disease progression.
Eligibility Ages Eligible: 18 Years
Genders Eligible:  Both
Accepts Healthy Volunteers:  No
In order to be in this trial, you must meet the enrollment criteria. Below is a list of some of the enrollment criteria.
  • You have been diagnosed with head and neck cancer (also called squamous cell carcinoma of the mouth)
  • You have Stage I or Stage II disease (a single mouth tumor which has not spread to other areas of the body)
  • Surgery to remove your tumor is recommended
  • You have not received any prior therapy for head and neck cancer (e.g. radiation or chemotherapy)
  • You are able to carry out your normal daily activities
  • Study Location
    University of Alabama, Birmingham
    Birmingham, Alabama, 35233
    Contact N/A

    Information objtained from ClinicalTrials.gov, on 10/1/2014. For additional information about this and other clinical trials, visit http://clinicaltrials.gov.
    Please refer to this study by its ClinicalTrials.gov identifier: NCT00050388


    Back to Search Results